Abstract: Platelet reactivity plays a pivotal role in the pathogenesis of ischemic adverse events during and after acute coronary syndromes (ACS), and percutaneous coronary intervention (PCI). Glycoprotein (GP) IIb/IIIa inhibitors are the strongest antiplatelet agents currently available on the market and three different compounds, namely abciximab, tirofi ban, and eptifi batide, have been approved for clinical use. Abciximab has been investigated in the clinical fi eld far more extensively than the other GPIIb/IIIa inhibitors. Abciximab is an anti-integrin Fab fragment of a human -mouse chimeric monoclonal antibody with high affi nity and a slow dissociation rate from the GP IIb/IIIa platelet receptor. Abciximab, given shortly before the coronary intervention, is superior to placebo in reducing the acute risk of ischemic complications (EPIC, EPISTENT, EPILOG trials); moreover, in the ISAR-REACT 2 study abciximab has been shown to reduce the risk of adverse events in patients with non ST-segment elevation ACS who are undergoing PCI even after optimal pre-treatment with 600 mg of clopidogrel. Finally, abciximab has been also used in abciximab-coated stent, with only bolus administration regimen and for direct intracoronary use with promising results that may extend and/or modify its current use in clinical practice in future.
Platelet reactivity plays a pivotal role in the pathogenesis of ischemic cardiovascular disorders (Kabbani et al 2001) .
Both platelet activation and aggregation have been shown to be heightened in the setting of acute coronary syndromes (ACS) and current evidence supports the concept that spontaneous (Kabbani et al 2003) or drug-modulated (Matetzky et al 2004) propensity to platelet-clot formation is a strong and independent predictor of clinical outcome. Blocking platelet aggregation with various agents acting on different molecular pathways has been consistently demonstrated to be of unequivocal benefi t in broad population of patients. Among the proposed pharmacological targets for antiplatelet therapy, the glycoprotein (GP) IIb/IIIa receptor continues to be among the most promising (Topol et al 1999) . GPIIb/IIIa, the αIIB/ß3 integrin, is a plateletspecifi c adhesion receptor with broad specifi city for a number of ligands, most notably fi brinogen, von Willebrand factor (vWF), and prothrombin. αIIB/ß3 integrin is the most abundant platelet membrane GP. GPIIb/IIIa mediates the formation of platelet aggregates via vWF and soluble fi brinogen. Platelet stimulation by soluble agonists (thrombin, adenosine diphoshate, and thromboxane A2) causes conformational changes of the receptor with subsequent transformation from a low-into a high-affi nity state, allowing for ligand (circulating fi brinogen or vWF) binding. This conformational change of GPIIb/IIIa is not due to any direct action of the agonists on the receptor but results directly from receptor-mediated stimulation of intracellular signalling pathways that enhance ligand-affi nity of GP IIb/IIIa. All GP IIb/IIIa antagonists react with the resting and active forms of αIIB/ß3 integrin and therefore all agents bind to non-stimulated and stimulated platelets, although with different affi nities towards the receptor and in different binding sites (Schror et al 2003) . The GPIIb/IIIa inhibitors are a class of agents blocking the binding of fi brinogen to activated GPIIb/IIIa, thereby inhibiting platelet-platelet interaction and thrombus formation. GPIIb/IIIa inhibitors have been shown to reduce secondary complications following percutaneous coronary intervention (PCI). Three GPIIb/IIIa inhibitors, abciximab, tirofi ban, and eptifi batide, have been approved for clinical use in the United States and other countries (Table 1) . They are given by intravenous administration whereas development of oral GP 2b/3a inhibitors has been discontinued due to negative or even paradoxical fi ndings in clinical trials. This paper will focus on abciximab which provided robust, consistent, and signifi cant reduction in death or myocardial infarction (MI) in several PCI trials.
Pharmacodynamics and pharmacokinetics of abciximab
Abciximab is an anti-integrin Fab fragment of a human -mouse chimeric monoclonal antibody with high affi nity and a slow dissociation rate from the GPIIb/IIIa platelet receptor (Mager et al 2003; Schror et al 2003; Gowda et al 2004; Silva et al 2004; Atwater et al 2005) . It has a short plasma half-life of 10-30 minutes, but a long biologic half-life due to its strong affi nity to the GPIIb/IIIa receptor (67% bound to the receptor). It remains bound in circulation for up to 15 days with minimal residual activity. Its receptor occupancy is 30% at 8 days and 10% at 15 days. Despite prolonged receptor occupancy, platelet function returns to baseline 12-36 hours after therapy cessation mainly due to rapid platelet turnover (Mager et al 2003; Schror et al 2003; Gowda et al 2004; Silva et al 2004; Atwater et al 2005) . Abciximab-coated platelets can be detected in the circulation for at least 2 weeks after treatment. Complete receptor blockade is obtained at approximately 5 μg/mL (100 nM). The binding site of abciximab is located at the ß-chain of the GPIIb/IIIa receptor and is different from the binding site for the low-molecular-weight inhibitors eptifi batide and tirofi ban (Mager et al 2003; Schror et al 2003; Silva et al 2004; Gowda et al 2004; Atwater et al 2005) . The advantage of low plasma concentrations and the high receptor affi nity allows reversibility of signifi cant bleeding time with platelet transfusions. Mechanistically, the large antibody fragment (molecular weight about 50 kD) causes a steric hindrance of access of ligands to their binding pocket. This also explains its almost equimolar potency (kD: 7 nM) for inhibition of the other ß3 integrin av/ß3, the vitronectin receptor at the surface of vascular cells, ie, the endothelium and vascular smooth muscle. At lower affi nity (kD: 160 nM), abciximab also interacts with the activated MAC-1 receptor on leukocytes (Mager et al 2003; Schror et al 2003; Gowda et al 2004; Silva et al 2004; Atwater et al 2005) . These additional interactions with other integrins are not generally shared by other two low-molecular-weight antagonists. The clinical relevance of occupancy of non-GP IIb/IIIa receptors by abciximab has not been established. Abciximab has been shown to elicit an antibody response, particularly after readministration, most likely because of its large size and murine origin. On repeat dosing, this antigenicity of abciximab may increase the risk of thrombocytopenia (Aster 2005) .
Principal clinical studies using abciximab
Given shortly before the PCI, abciximab is superior to placebo in reducing the acute risk of ischemic complications ( Table 2 ). Two studies, CAPTURE (The CAPTURE Investigators 1997) (the Chimeric 7E3 Antiplatelet in Unstable Angina Refractory to Standard Treatment study) and GUSTO IV-ACS (The GUSTO IV-ACS Investigators 2001) (the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries study) have evaluated the effi cacy and safety of abciximab in the context of different management strategies for patients with non ST-segment elevation ACS (NSTEACS). In the CAPTURE (The CAPTURE Investigators 1997) study, 1265 patients who were admitted with unstable angina and who continued to have refractory ischemia underwent cardiac catheterization. Patients who were deemed good candidates for PCI were randomized into abciximab therapy for 18-24 hours before angioplasty and 1 hour after, or placebo treatment with coronary angioplasty. The primary composite end point at 30 days of death, MI, or urgent repeat intervention for recurrent ischemia was signifi cantly less in patients who received abciximab (11.3% abciximab vs 15.9% placebo; p = 0.012). The majority of benefi t with abciximab was derived with reduction of peri-procedural MI (2.6% abciximab vs 5.5% placebo; p = 0.009), and a reduction in MI prior to intervention was also observed (0.6% abciximab vs 2.1% placebo; p = 0.0029). However, this favorable effect was lost at 6 months in the whole cohort of patients. It should be emphasized that greater benefi t from platelet GPIIb/IIIa Abciximab: a clinical review inhibitor therapy is mainly seen in NSTEACS patients who present with elevated baseline cTnT levels. Indeed, in this subset of patients the rates of death or MI at 6 months were profoundly reduced in the abciximab-treated cohorts even at 6 months (9.5% abciximab vs 23.9% placebo; p = 0.002).
The GUSTO IV-ACS (The GUSTO IV-ACS Investigators 2001) trial showed no signifi cant benefi t to abciximab in the medical management of NSTEACS. In the GUSTO IV-ACS (The GUSTO IV-ACS Investigators 2001), PCI was discouraged by the protocol and ultimately it was performed only in 1.6% of patients within 48 hours and in 19% within 30 days. Abciximab was associated with a trend towards higher early mortality (at 48 hours) than in the placebo arm. There was also a lack of any therapeutic benefi t at 30 days. Thus, the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines (Braunwald et al 2002) give a class III recommendation (either not effective or potentially harmful) for the addition of abciximab to standard antithrombotic therapy in patients in whom PCI is not planned. The negative results of the GUSTO IV-ACS trial may be explained by the lack of access to timely revascularization which is in keeping with the results of several other trials based on the use of GPIIb/IIIa inhibitors. All these landmark investigations were conducted in the pre-clopidogrel era. Thus, patients were randomized to abciximab vs placebo on a background of aspirin alone as antiplatelet agent.
To assess the hypothesis that abciximab may be a useful therapy in patients with NSTEACS undergoing PCI, even after pretreatment with a 600 mg loading dose of clopidogrel, the ISAR-REACT 2 (Kastrati et al 2006) (the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment study) has been designed. Patients with an episode of angina (with an accelerating pattern, or prolonged, or recurrent episodes at rest, or with minimal effort) within the preceding 48 hours, accompanied by an elevated troponin level or a new fi nding of ST-segment depression or new or presumed new bundle-branch block undergoing PCI were enrolled, treated with 500 mg of oral or intravenous aspirin plus 600 mg clopidogrel, and randomized to abciximab or placebo. As result, a 25% reduction of the risk of recurrent ischemic events among patients assigned to abciximab was observed. Notably, the gradient in favor of abciximab was seen for all components of the primary end point (death, MI, and target vessel revascularization), although none reached statistical signifi cance when considered individually. The adverse event rate observed in patients without an elevated troponin level was similar to that seen previously in the fi rst ISAR-REACT trial (Kastrati et al 2004) (Table 2 ). In contrast, among patients with an elevated troponin level, the risk of recurrent ischemic events was considerably higher than that in those without elevated troponin levels and was reduced by 29% by abciximab.
When taken together current evidence suggests that the benefi t of abciximab over placebo is proportional to the risk status of the patients. This notion should be kept in mind when interpretating the apparently negative results observed with abciximab in the ISAR-REACT study (Kastrati et al 2004) .
Several trials have been conducted to test the role of abciximab in the setting of ST-segment elevation MI (STEMI). Recently, a meta-analysis has been published reporting 3-years follow-up data of 1101 patients presenting for primary PCI and stenting of STEMI randomized to abciximab or placebo (Montalescot et al 2007) . This analysis included data from ADMIRAL (Montalescot et al 2001) (the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction regarding Acute and Long-term Follow-up study), ISAR-2 (Neumann et al 2000) , and ACE (Antoniucci et al 2003) (the Abciximab and Carbostent Evaluation study) trials. The primary endpoint of death or re-infarction was significantly reduced from an estimated cumulative hazard rate of 19.0% with placebo to 12.9% with abciximab. The mortality rate was reduced from an estimated cumulative hazard rate of 14.3% in the placebo arm to 10.9% in the abciximab arm. Major bleedings were 2.5 and 2% with and without abciximab, respectively. In the control arm, both the death or MI cumulative hazard rate (54 vs 13.5%) and mortality rate (39.7 vs 10.1%) were 4-fold higher in diabetics than non-diabetics. Abciximab provided a signifi cant benefi t on the primary endpoint for diabetics. A meta-regression analysis of randomized trials with abciximab in the primary PCI setting confi rmed and expanded this observation (De Luca et al 2006) .
Principal clinical studies comparing abciximab to others GP IIb/IIIa inhibitors Abciximab vs tirofi ban
In the TARGET trial (Topol et al 2001) (the do Tirofi ban and Abciximab Give Similar Effi cacy Outcomes study), 5308 patients scheduled to urgent or elective PCI were enrolled and randomized to tirofi ban (bolus 10 μg/kg and infusion of 0.15 μg/kg/min) or abciximab (bolus 25 mg/kg and infusion 0.125 μg/kg). All patients received aspirin, dose-adjusted heparin and, when possible, loading dose of clopidogrel of 300 mg 2-6 hours before the procedure. The primary end point, a composite of death, nonfatal MI and urgent targetvessel revascularization within 30 days after the index procedure, occurred more frequently in the tirofi ban group than in the abciximab group (7.6% vs 6%, p = 0.03). The superiority of abciximab was entirely driven by a higher rate of peri-procedural MI in the tirofi ban arm, mortality rate and the need for target vessel revascularization completely overlapping between the two study arms. Interestingly, plotting the incidence of MI in the two study groups in the fi rst 72 hours after randomization (Figure 1) , it becomes clear that this had already started to diverge in the tirofi ban arm 8 hours after randomization with respect to abciximab but after 24 hours the two curves were running parallel, which implies that the excess of MI in the tirofi ban group occurred between 8 and 24 hours after randomization. Since the occurrence of MI in the trial was defi ned as the fi nding of levels of the MB isoform of creatine kinase that were at least 3 times the upper limit of the normal range in 2 separate blood samples, which were taken every 6 hours after the index procedure, these fi ndings altogether strongly suggest that the excess of MI in the tirofi ban arm was indeed generated directly during the procedure, a few minutes after the bolus of the two drugs were administered. However, starting from the fi rst day after the procedure, the event rate in the two groups remained similar, thus diluting the small early excess of events in the tirofi ban arm, which explains the fi nding of a similar overall event rate at 6 and 12 months. Several studies (Batchelor et al 2002; Ernst et al 2004) showed that, soon after the bolus, the degree of early platelet inhibition was higher after abciximab than after tirofi ban (dosage used in the randomized effi cacy study of tirofi ban for outcomes and restenosis -RESTORE -(The RESTORE Investigators 1997) and TARGET studies (Topol et al 2001) , thus offering more protection during PCI, where iatrogenic vessel injury is known to require almost complete platelet inhibition. As a consequence of the suboptimal platelet inhibition achieved soon after the RESTORE regimen (The RESTORE Investigators 1997), subsequent dose-ranging studies have led to an increase in the tirofi ban bolus dose from 10 to 25 μg/kg (Schneider et al 2002) . , or change in infarct-zone wall motion score index and global LV ejection fraction at 30 days in the study by Danzi et al (2004) . In the EVEREST trial (Bolognese et al 2005) , NSTEACS patients were randomized to upstream vs in-catheterization-laboratory initiation of GPIIb/IIIa antagonists. The upstream arm received the standard dose of tirofi ban, as used in the PRISM-PLUS trial (the PRISM-PLUS Investigators 1998) (the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients limited by Unstable Signs and Symptoms study). The in-catheterization laboratory arm received either abciximab or tirofi ban with high dose bolus in a randomized fashion. The results, although preliminary, are intriguing. The patients in the upstream arm had better myocardial perfusion both on arrival in the catheterization laboratory and at the end of their procedure, as compared with the higher-dose tirofi ban and abciximab patients, who had therapy initiated in the catheterization laboratory. It is plausible that upstream administration of GPIIb/IIIa inhibitors may not only prevent thrombus formation (and propagation) but may also lead to dissolution of platelet aggregates. Thus, the upstream use of the agent may lead to a lower thrombus load at the start of the procedure, hence less potential for distal embolization during the procedure.
Abciximab vs eptifi batide
There no are randomized clinical trials comparing abciximab with eptifi batide, but observational and/or pharmacological studies have been conducted and different information may be extrapolated.
In the COMPARE trial (Batchelor et al 2002) (the Comparison Of Measurements of Platelet Aggregation with Aggrastat, Reopro, and Eptifi batide study), 70 ACS patients undergoing PCI were randomized to receive abciximab, eptifi batide, or tirofi ban at doses used in the EPISTENT (The EPISTENT Investigators 1998), PURSUIT (the PURSUIT Investigators 1998) (the Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy study), and PRISM-PLUS/RESTORE trials, respectively. Platelet aggregation (PA) in response to 20 μmol/L of adenosine diphosphate was measured with turbidimetric aggregometry early (15 and 30 minutes) and late (4, 12, and 18-24 hours) after drug initiation. Although all regimens provided effective platelet inhibition, the tirofi ban-RESTORE regimen produced less inhibition at 15-30 minutes compared with abciximab or eptifi batide. With continued infusion of the tirofi ban-RESTORE regimen, platelet inhibition increased to levels comparable to those achieved by abciximab and eptifi batide. In contrast, although the abciximab regimen consistently inhibited PA early on, more recovery of PA occurred with continued infusion (4-12 hours). Of the four regimens evaluated, the eptifi batide regimen provided the most consistent platelet inhibition throughout infusion (Figure 2) . Schweiger et al (2003) reported the comparison of 2 sequential cohorts of consecutive patients undergoing PCI who received abciximab or eptifi batide. A total of 319 patients were treated with abciximab and 301 with eptifibatide. There were no differences in the incidence of major adverse cardiac events in hospital or at 30 days. Raveendran et al (2007) reported the outcome of 576 patients underwent primary PCI and treated with GPIIb/IIIa receptor antagonists. Abciximab was given to 327 patients (57%) and eptifi batide to 249 (43%). Observed rates of inhospital death or MI did not differ between groups. This result persisted with adjustment for various patients.
Although these data are interesting, head to head randomized controlled trials would be desirable. Table 3 summarizes the indication for the use of abciximab according to current American and European guidelines. As reported, abciximab is currently recommended for the administration in the cath-lab immediately before coronary revascularization in patients with high risk NSTEACS.
Current guidelines
Recently the ACUITY and the ACUITY-TIMING have been published (the Acute Catheterization and Urgent Intervention Triage Strategy study) trials (Stone et al 2006a, b . The fi rst study used a 2 × 2 factorial design to compare a heparin with or without GPIIb/IIIa inhibition vs bivalirudin with or without upstream GPIIb/IIIa inhibition; a third arm tested bivalirudin alone with provisional use of GPIIb/IIIa inhibition. Authors found that bivalirudin + GPIIb/IIIa inhibitors compared with heparin + GPIIb/IIIa inhibitors was non-inferior on the composite of ischemia and major bleeding. As a contrary, bivalirudin alone vs heparin + GPIIb/IIIa inhibitors resulted in a non-inferior rate of composite ischemia and in a reduction of major bleeding. In the second study, two different strategies were compared: deferred selective use of GPIIb/IIIa inhibitors vs routine upstream administration of GPIIb/IIIa inhibitors. They found that a deferred selective use of GP2b/3a inhibitors resulted in a reduced rate of bleeding but a trend towards higher ischemic events. Regarding ACUITY (Stone et al 2006a) and ACUITY-TIMING (Stone et al 2006b ) trials, two issues should be considered before their results may directly be applied to clinical practice: i) the median time between onset of medical therapy and catheterization was remarkably short (~4 hours), thus the results of ACUITY TIMING cannot be extrapolated to those scenarios where longer upstream infusion (24-48 hours) is carried out; ii) in the bivalirudin-alone group, the patients who did not receive clopidogrel before PCI showed a signifi cantly worse ischemic outcome.
Safety and tolerability
The major concerns with use of GPIIb/IIIa receptor antagonists are the potential risk of major bleeding and thrombocytopenia.
Bleeding
Bleeding is generally increased in patients receiving GPIIb/IIIa compared to heparin alone, mainly because of excessively high heparin dose in the treated arm. Heparin dose reduction drastically decreases bleeding rates with no impact on ischemic endpoints. Thus, risk of bleeding can be reduced by the use of low-dose adjunctive heparin, early sheath removal, and meticulous post-procedure care of the vascular access site. The increase in bleeding complications related to use of abciximab might be due to its slowly reversible antiplatelet effects, which may be of concern in patients in whom an emergency coronary artery bypass graft is required. In such a scenario, platelet transfusion may be required to control bleeding.
Thrombocytopenia
In clinical trials of abciximab and in subsequent experience, it was found that about 1% of patients given this drug experienced acute, often severe thrombocytopenia (Aster 2005) . After a second exposure to the drug, the rate for this complication rises to about 4% (Aster 2005) . In some instances, the onset of thrombocytopenia may be accompanied by fever, dyspnea, hypotension, and even frank anaphylaxis, occurring soon after starting the drug. Although most patients with abciximab-associated thrombocytopenia recover uneventfully, life-threatening bleeding has been described, including intracranial hemorrhage (Aster 2005) . Although abciximab-induced thrombocytopenia usually occurs within a few hours of starting therapy with the drug, a subgroup of patients has been described in whom the drop in platelet levels occurred 5-8 days after the drug was administered (Aster 2005) . Direct evidence for the immune destruction of platelets in patients who have received abciximab was provided by studies showing that a group of patients who developed severe thrombocytopenia after a second exposure • High risk NSTEACS patients not pretreated with GP IIb/IIIa inhibitors and proceeding PCI.
• For high risk NSTEACS patients in whom PCI has been selected as a post-angiography management strategy, it is reasonable administer abciximab if a GP IIb/IIIa has not been started before diagnostic angiography.
II
• It is reasonable to start treatment with abciximab as early as possible before primary PCI (with or without stenting) in patients with STEMI.
• Abciximab as ancillary therapy during primary PCI.
• Stable CAD patients treated with PCI of complex lesions, threatening/actual vessel closure, visible thrombus, no/slow refl ow.
• When anatomy is known and PCI planned to be performed whitin 24 hours with GPIIb/IIIa inhibitors, most secure evidence is for abciximab.
• Abciximab administration in high risk NSTEACS patients in whom bivalirudin was selected as anticoagulant.
III
• Abciximab administration in ACS patients in whom PCI is not planned.
• Abciximab is in fact unnecessary in patients treated with a non invasive strategy.
Abbreviations: ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; PCI, percutaneous coronary intervention; NSTEACS, non ST-segment elevation acute coronary syndrome; STEMI, ST-segment elvation myocardial infarction.
to the drug all had strong IgG and/or IgM antibodies that reacted with abciximab-coated platelets in a fl ow cytometric assay. There are no published reports characterizing antibodies in patients who developed thrombocytopenia after a fi rst exposure to abciximab, although unpublished observations suggest that antibodies similar to those found in patients given abciximab a second time are responsible for platelet destruction in most cases. These antibodies can 
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be found in pretreatment blood samples, indicating that they are naturally occurring. A platelet count should be performed routinely before and within 2-6 hours after starting treatment in any patient given abciximab to enable the early diagnosis of druginduced thrombocytopenia (Aster 2005) . Some patients who develop thrombocytopenia are asymptomatic or exhibit only scattered petechial hemorrhages. Others experience bleeding from sites of catheterization, gastro-intestinal hemorrhage, or hematoma formation. Because the function of platelets remaining in the circulation is impaired by the inhibitor, all patients with this complication should be considered to be at risk for bleeding, and those with signifi cant hemorrhage should be given platelet transfusions.
Patients who have received abciximab are at risk for a longer period of time because platelet function is impaired for up to 1 week, and thrombocytopenia sometimes persists for 3-5 days. On the basis of limited experience, it appears that patients who are sensitive to abciximab can safely receive tirofi ban or eptifi batide at a later time. It is likely that the converse is true, but this has not yet been documented.
Contraindications
The contraindications to use of abciximab are generally similar to those of thrombolytic agents and are summarized in Table 4 .
Novel approaches to use abciximab

Abciximab-coated stent
Differently from other platelet GPIIb/IIIa receptor blockers, abciximab binds to MAC-1 (CD11b/18) on vascular endothelial cells and macrophages, thereby inhibiting infl ammatory responses and smooth muscle cell proliferation after vascular injury. Furthermore, abciximab is known to bind to the vitronectin receptors found on platelets and vascular endothelial and smooth muscle cells and exert an inhibitory effect on migration and proliferation of smooth muscle cells after acute vessel injury. Thus, abciximab-coated stents have been created, on the hypothesis of their inhibitory effects in coronary restenosis and their prevention effect in subacute stent thrombosis. Previous studies (Hong et al 2004) demonstrated that abciximab-coated stents were safe and effective in the prevention of coronary restenosis in humans. Abciximab-coated stents have been tested also in 96 patients with acute MI (Kim et al 2006) treated with primary PCI and randomly allocated into 2 groups: group I received abciximab-coated stents, and group II received bare metal stents. One patient in group II had reinfarction and target lesion reintervention during hospital stay.
At coronary angiography follow-up late loss was signifi cantly lower in group I than group II. In-stent restenosis rate was lower in group I than group II. During 1-year follow-up, 2 patients in group II (4.1%) had MI, whereas no patients in group I suffered MI. Target lesion revascularization and total major adverse cardiac events rates were lower in group I than in group II (10.4% vs 20.8%, p = 0.261, and 10.4% vs 25.0%, p = 0.107, respectively). It is important to note, in this study, the absence of episodes of acute MI by acute or subacute thrombotic occlusion during 1-year clinical follow-up in the patients who received abciximab-coated stents. The sample size of the study was small, but it is plausible to speculate that platelet aggregation was effectively inhibited with use of abciximab, and this effect could be maintained for a long-term period.
Bolus-only use
Traditionally, abciximab is administered as an intravenous bolus, followed by a prolonged infusion (12 hours). Many patients undergoing PCI (both in the United States and worldwide) do not receive a GPIIb/IIIa inhibitors, in part owing to concerns about bleeding and cost. In the present era of oral thienopyridines, where patients are preloaded with a high dose of clopidogrel (300-600 mg) in order to achieve an antiplatelet effect within 2-4 hours, the relevance of a prolonged abciximab infusion may be questionable, particularly given the widespread use of stents that have virtually eliminated the problem of abrupt closure. Moreover, the bolus of abciximab represents ~75% of the total dose, and pharmacological data have shown that a single bolus (0.25 mg/kg) of abciximab induces Ͼ80% of platelet aggregation inhibition and that this effect is prolonged for several hours. The prolonged abciximab infusion, as opposed to bolus-only administration, may contribute to increased bleeding complications and thrombocytopenia, without an incremental anti-ischemic benefi t. The avoidance of prolonged infusion of abciximab has the potential to not only reduce vascular complications, but also to reduce the length of hospital stay and total cost of the procedure. retrospectively analyzed consecutive patients (n = 1001) who underwent PCI and received an unfractionated heparin and bolus-only GPIIb/IIIa inhibitors regimen. All patients received clopidogrel and aspirin prior to PCI. Eptifi batide was used in the 58.3% of the cases, abciximab in the 37.3%, and tirofi ban in the 4.3%. A bolusonly GPIIb/IIIa inhibitors strategy appears to maintain the anti-ischemic benefi ts, with the added benefi t of reduced bleeding complications and the potential for reduced cost and shortened length of hospital stay.
In the EASY trial (the Early Discharge after Transradial Stenting of Coronary Arteries study), 1005 patients were randomized after a bolus of abciximab and uncomplicated transradial percutaneous coronary stent implantation either to same-day home discharge and no infusion of abciximab or to overnight hospitalization and a standard 12-hour infusion of abciximab. The primary composite end point of the study was the 30-day incidence of any of the following events: death, MI, urgent revascularization, major bleeding, repeat hospitalization, access site complications, and severe thrombocytopenia. They found that same-day home discharge after uncomplicated transradial coronary stenting and bolus only of abciximab is not clinically inferior, in a wide spectrum of patients, to the standard overnight hospitalization and a bolus followed by a 12-hour infusion.
In the EPIC trial, 2099 patients scheduled to high-risk PCI were enrolled and randomized to 3 treatment arms: bolus and 12-hour infusion of placebo, abciximab bolus of 0.25 mg/kg plus 12-hour placebo infusion, and abciximab bolus plus 12-hour infusion (10 μg/min). It is important to note that thienopyridines were not administered to patients in the EPIC as protocol mandated balloon angioplasty only. Accordingly, stent was used in the EPIC only to treat imminent or complete abrupt closure of the vessel undergoing angioplasty. The primary end point of the EPIC trial was a composite of death, MI, or urgent intervention during the fi rst 30 days after randomization. Recently, an analysis of the EPIC outcomes at 6-hour intervals during the fi rst 24 hours after PCI to identify any early benefi t derived from the abciximab bolus-only arm has been published . This analysis demonstrates a signifi cant reduction in the composite end point of death, MI, or urgent intervention at 6 hours in the abciximab bolus-only group compared with the placebo group. After 6 hours and throughout the fi rst 24 hours post-procedure, a numerical reduction was apparent, but statistical signifi cance was not achieved. The fact that a bolus-only strategy appears to be effective in the fi rst 6 hours may be relevant in the context of stenting and routine administration of a loading dose of clopidogrel.
Intracoronary use
All clinical trials studied solely the intravenous administration of abciximab and there is only limited information on the efficacy of intracoronary administration of abciximab. In patients with ACS, intracoronary administration of abciximab with very high local concentrations of the antibody may be favorable in dissolution of thrombi and microemboli with subsequent better and faster recovery of myocardial microcirculation and reduction of major adverse cardiac events (MACE). Wöhrle et al (2003) reported a series of 403 consecutive patients with unstable angina or acute MI undergoing emergency coronary intervention retrospectively stratifi ed according to the method of application of abciximab (20 mg bolus of abciximab was given intravenously in 109 patients and intracoronarily in 294 patients, followed by 12 hours of intravenous infusion of 10 mg in both groups). At 30 days, the incidence of MACE (death, MI, urgent revascularization) was signifi cantly lower in the patients with intracoronary compared with intravenous administration of abciximab (10.2% vs 20.2%; p = 0.008), which was independent from stenting in multivariate analysis. The effect was most pronounced in patients with pre-procedural TIMI 0/1 fl ow (MACE: intracoronary 11.8% vs intravenous 27.5%, p = 0.002). Burzotta et al (2003) , with their angiographic data in a limited subset of patients, extended the fi ndings of Wöhrle, suggesting that in patients with ACS, the reduction of angiographically evident thrombus obtained with intracoronary administration of abciximab translates into an acute improvement of coronary blood fl ow.
Conclusions
Several randomized trials have reported the ability of abciximab to reduce death or MI when used as adjunctive therapy to PCI. Accordingly, abciximab is recommended by the American College of Cardiology/American Heart Association and European Society of Cardiology guidelines (Braunwald et There is increasing evidence that treatment with clopidogrel prior to PCI prevents postprocedural ischemic complications. Several studies have shown that a 600-mg loading dose of clopidogrel, compared with the usual 300-mg dose, is as safe and is signifi cantly more rapidly acting. However, it is known that the antiplatelet effect provided by 600 mg of clopidogrel is not suffi cient for patients with STEMI or moderate-high risk ACS undergoing PCI (Kastrati et al 2006) . Thus, GPIIb/IIIa inhibitors show a critical role in the current management of high risk patients. It is plausible that in the future the abciximab bolus-only scheme for facilitating PCI may become a more widespread choice to maintain effi cacy while minimizing safety and costs. Randomized controlled trials are currently underway.
Current data suggest that there are no differences between the three GPIIb/IIIa inhibitors approved for clinical use in terms of degree of platelet inhibition, particularly after the revision of the tirofi ban bolus dose. Nevertheless, abciximab still today remains the GPIIb/IIIa inhibitor with greater evidence of benefi t from randomized clinical trials showing a signifi cant and consistent reduction of death and reinfarction in high risk patients undergoing PCI.
